Both HOLX and Myriad Genetics are longstanding key players in the Molecular Diagnostics space. But which one is a better investment now?

In a report released yesterday, Puneet Souda from Leerink Partners maintained a Hold rating on Myriad Genetics (MYGN – Research Report). The ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that ...

Myriad Genetics (MYGN) announced that the Journal of Clinical Psychopharmacology has published a study showing those with major depressive ...

Gov. Brian Kemp signed into law an overhaul of the state's litigation system aimed at bringing down insurance costs.